The impact of major depressive disorder on glycaemic control in type 2 diabetes: a cohort study using UK Biobank primary care records

Alexandra C Gillett[1,2†], Saskia P Hagenaars[1,2†], Francesco Casanova[3], Katherine G Young[3], Harry Green[3], Cathryn M Lewis[1,2,4‡], Jess Tyrrell[3‡]

† contributed equally

‡ joint senior authors

Affiliations

1. Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
2. NIHR Maudsley Biomedical Research Centre, South London and Maudsley NHS Trust, London, UK
3. Clinical and Biomedical Science, Institute of Health and Life Sciences, University of Exeter, Exeter, UK
4. Department of Medical and Molecular Genetics, Faculty of Life Sciences and Medicine, King's College London.

Corresponding author:

Alexandra C Gillett

Social, Genetic and Developmental Psychiatry Centre,

Institute of Psychiatry, Psychology and Neuroscience,

King's College London,

London, UK

alexandra.a.gillett@kcl.ac.uk

Word count

Abstract: 242

Manuscript: 3481

Abstract

Background

This study evaluates longitudinal associations between glycaemic control (mean and within-patient variability of glycated haemaglobin (HbA1c) levels) in individuals with type 2 diabetes (T2D) and major depressive disorder (MDD).

Methods

In UK Biobank (UKB), T2D was defined using self-report, linked primary care records, prescription records and hospital episode statistics, then validated using polygenic scores. Repeated HbA1c measurements were extracted from primary care records and baseline UKB biomarker measures, and used as the outcome in mixed effects models to investigate the association between MDD and glycaemic control over a maximum 10-year T2D disease duration. The exposure investigated was MDD, with subgroups defined by the relative timings of MDD and T2D diagnoses (no MDD, MDD diagnosis pre-T2D or post-T2D). Multiple imputation (n=9264) and complete case (n=4233) analyses were performed.

Results

The T2D diagnostic criteria were robustly associated with T2D polygenic scores. Using mixed effect models and multiple imputation (7.6 year median follow-up), temporal trends in mean HbA1c did not differ by MDD subgroup. Within-patient variability in HbA1c was 1.14 (95% CI: 1.12-1.16) times higher in UKB participants diagnosed with MDD after T2D compared those with no MDD diagnosis. Complete case analyses results differed, but the substantial evidence against missingness being completely at random, suggests that complete case analysis will be biased.

Conclusions

These findings suggest closer monitoring to improve T2D control is important in individuals who develop MDD after T2D diagnosis. Further, the study highlights the importance of correctly accounting for missing data.

Key words: type 2 diabetes, major depressive disorder, HbA1c, longitudinal, epidemiology

Key messages

- Major depressive disorder (MDD) is associated with poorer glycaemic control and an increased risk of complications and mortality in individuals with type 2 diabetes (T2D). Research suggests that individuals diagnosed with MDD after T2D (post-T2D MDD) may be driving these associations, but the effect of diagnostic order on glycaemic control has not been investigated longitudinally.

- Using UK Biobank primary care records, we investigated whether post-T2D MDD is associated with poorer glycaemic control over the 10 years following a T2D diagnosis, as measured by mean HbA1c trends and within-patient HbA1c variability.

- Individuals with post-T2D MDD had greater within-patient variability in HbA1c compared to those with no MDD diagnosis, indicating poorer glycaemic control, but no difference in mean HbA1c was found. Individuals with pre-existing MDD had similar glycaemic control to those with no MDD.

- Results suggest the importance of considering within-patient variability in HbA1c, in addition to the mean, when investigating glycaemic control over time, and highlight the role of the relative timing of diagnosis for MDD and T2D in glycaemic control.

Introduction

Major depressive disorder (MDD) and type 2 diabetes (T2D) represent two substantial global health burdens. Previous studies have indicated bidirectional associations between MDD and T2D, with a meta-analysis demonstrating that adults with MDD had a 37% higher risk of developing T2D[1], and another study indicating a 15% higher risk of incident MDD in people with T2D at baseline[2].

Comorbid MDD and T2D are associated with poorer prognosis, with elevated risk of diabetic complications[3] and higher suicide risk[4]. The underlying mechanisms between these disorders and outcomes remain poorly understood, but could include lifestyle factors, non-adherence to T2D treatment, use of antidepressant medication or genetic factors[5]. The relative timing of MDD and T2D diagnoses may also impact T2D clinical characteristics, with a diagnosis of depression after T2D being linked with poor glycaemic control and a higher prevalence of diabetic complications, compared to T2D patients with no or with pre-existing depression[6].

To fully understand the relationship between MDD and T2D it is necessary to consider longitudinal data and monitor both MDD and T2D over time. Regular blood glucose monitoring is essential in T2D, with glycated haemoglobin (HbA1c) representing a reliable measure of long-term glycemia. Elevated and more variable HbA1c measurements are associated with increased risk of long-term diabetic complications, such as stroke and cardiovascular disease[7–9]. Poor glycaemic control may contribute to the differences in prognosis and clinical features observed in individuals with comorbid T2D and MDD.

Prior studies have shown mixed support for the bidirectional association between MDD and HbA1c[10], but many are limited to a cross-sectional design. A meta-analysis that considered longitudinal effects of depressive symptoms on HbA1c found that depressive symptoms associated with HbA1c across a mean follow-up of 3 years (*n*=3683 across six studies)[10]. Determining the impact of MDD on glycaemic control across time is crucial for ensuring appropriate clinical care is given to people with both MDD and T2D. Longitudinal studies, to date, have not explored the relationship between the relative timing of MDD and T2D diagnoses and HbA1c trends over time.

This study uses UK Biobank (UKB) primary care records to perform extensive longitudinal modelling of HbA1c in people with T2D in a retrospective, observational study, using information on MDD diagnosis. In the UK, HbA1c is measured by a general practitioner (GP) every 3-6 months in individuals with T2D[11]. Therefore, the linked primary care data available in UKB provides a unique opportunity to test the longitudinal relationship between HbA1c (mean values and variability) and MDD diagnosis over a maximum follow-up of 10 years. Three MDD subgroups are analysed: no MDD diagnosis, MDD diagnosis before T2D, and MDD diagnosis after T2D. We investigate the potential influence of missing data using multiple imputation methods and complete case analyses.

Methods

Study population

The UK Biobank (UKB) is a health study of ~500,000 individuals recruited between the ages of 40-70 years across the United Kingdom between 2006 and 2010[12]. Linked primary care records are available for ~230,000 individuals (46%) and include coded clinical events, routinely collected blood test results and drug prescriptions, providing patient information across time[13]. UKB participants with primary care records were classified into T2D cases and controls. To be a T2D case, a participant needed to meet T2D diagnostic criteria (outlined below), and have at least two HbA1c measurements. Cases were excluded if they had a primary care code specific to type 1 diabetes, an insulin prescription in the year after T2D diagnosis, or a prescription for multiple diabetic medications at T2D diagnosis. Controls were individuals who did not meet the T2D diagnostic criteria. To validate the T2D diagnostic criteria, T2D polygenic scores (PGSs) were tested in European ancestry participants meeting genetic quality control criteria[14] (Supplementary Methods (SuppMethods) 4). For the longitudinal analysis, we excluded participants if they: 1) were a T2D control, 2) had age at T2D diagnosis < 18 years, 3) had no recorded HbA1c measurements > 38 mmol/mol[15], 4) had a diagnostic code for bipolar, psychotic or substance-use related disorders[16], or 5) had a MDD diagnosis but no MDD diagnosis date (Figure 1).

Type 2 diabetes (T2D) diagnostic criteria

T2D was defined as any two of the following: a primary care diagnosis code for T2D (Supplementary Table (SuppTable) S1), an ICD9/ICD10 diagnosis code for T2D (SuppTable S2), any HbA1c measurement > 48 mmol/mol (6.5%), any prescription for glucose lowering medication, or a self-reported diagnosis for T2D where the self-reported age at onset was > 35 years old, with diagnosis date as the earliest occurrence (Figure 2).

Outcome measures

The outcome for the T2D diagnostic criteria validation was T2D case-control status for UKB participants of European ancestry with primary care records available. The outcome for the longitudinal analysis was repeated measures of HbA1c (mmol/mol) occuring after T2D diagnosis. HbA1c measurements were taken from primary care records (SuppTable S4) and UKB assessments. Measurements from primary care records were observed between 1997 to 2017, and older observations recorded in %-units were converted to mmol/mol[17].

Measurements before the participant's date of birth, or in the future, were removed. HbA1c measurements from the UKB recruitment visit (between 2006 and 2010), were measured via the biomarker panel and were combined with the primary care records. As HbA1c values from the UKB biomarker panel were, on average, lower than those from primary care, a previously validated correction was applied[18] (SuppMethods 3). A maximum follow-up period of 10 years from T2D diagnosis was considered.

Exposure

The exposure used in the longitudinal analysis was a three-level MDD subgroup variable. UKB participants required at least two diagnostic codes for a depressive disorder or episode to be classed as a MDD case[16]. Three MDD subgroups were created:

1) No MDD: individuals with T2D, without MDD,

2) Pre-T2D MDD: individuals diagnosed with MDD prior to T2D, and

3) Post-T2D MDD: individuals diagnosed with MDD after their T2D diagnosis.

We note modelling using a MDD polygenic score (PGS) as an exposure was also performed, to test if a higher genetic liability to depression altered glycaemic control. However, results were null (SuppMethods 11).

Covariates

Longitudinal analyses were adjusted for participant sex, year of birth, UKB assessment centre, year of T2D diagnosis, age at T2D diagnosis, HbA1c at T2D diagnosis, genetic ancestry (defined as the five 1000 Genome super populations, and genetically inferred using the ukbkings package[19]), time and diabetic medication. Time was T2D disease duration, with T2D diagnosis being the indexing date. Glucose lowering medication for each participant at each HbA1c observation was identified using prescription records up to three months prior to HbA1c measurement (SuppMethods 2). We assigned each observation to a medication category with: M0 defined as 'no medication', M1 as 'metformin or a single medication' (monotherapy), M2 as 'two medications', and M3 as either '3 or more medications' or 'insulin'. Two medication variables were then created: 1) a binary variable indicating monotherapy at T2D diagnosis versus no prescribed T2D medication (M0 vs M1 at diagnosis, with individuals in M2 and M3 removed) and 2) a time-varying medication variable using the four categories M0 – M3.

Statistical analysis

All analyses were performed using R version 4.1.1, and results plotted using ggplot2.

Validation of T2D diagnostic criteria: To validate the T2D definition, we tested whether PGSs for T2D[20] predicted T2D case-control status . PGSs calculated using PRSice v2[21,22] at eleven *P*-value thresholds were tested for association with T2D case-control status, adjusting for six genetic ancestry principal components, assessment centre and genetic batch effect (SuppMethods 5).

Longitudinal analysis: Linear mixed effects models (MEMs) with a continuous-time autoregressive 1 (CAR1) residual correlation structure were used to investigate longitudinal associations between HbA1c and MDD subgroup using the nlme package[23,24]. Models included three components: fixed effects, random effects and, within-subject residual variance and correlation. The fixed effects model describes mean HbA1c over time and how this changes with MDD subgroup. To allow for a non-linear temporal trend in mean HbA1c, T2D disease duration (time) was modelled using a restricted cubic spline with four knots[25,26]. The covariates listed above were adjusted for, plus interactions between the time-splines and 1) HbA1c at T2D diagnosis and 2) the medication variables. Main effects and interactions with the time-splines were included for the MDD subgroup variable, with the 'No MDD' group as the reference, and associations tested using Wald tests. The random effects model, which allows each participant to differ from the study mean, included a random intercept and linear random slope for time. The within-subject correlation captures any residual correlation between the repeated measures from the same individual. A CAR1 error structure was used, which allows measurements taken closer in time to have a higher correlation than those taken further apart. Residual within-subject HbA1c variability was allowed to differ by MDD subgroup, and likelihood ratio tests (LRTs) were used to test for exposure-related heterogeneity in residual variation. Details on all covariates included are given in SuppTable S5.

HbA1c at T2D diagnosis had a high level of missingness (54%), but 79% of participants had HbA1c measurements within a six month window. Multiple imputation (MI) using the Amelia package[27] was used to generate 15 MI datasets (SuppMethods 7). MEM estimates in MI datasets were pooled using Rubins method, with pooled Wald-like *P*-values presented for the fixed effects[28,29]. Since parameter estimates relating to restricted cubic splines are difficult to interpret, we present results using plots of predicted HbA1c[30,31]. Pooled predictions for mean HbA1c over time (the fixed effects model), with 95% confidence intervals (CIs), were generated for a range of example individuals[32]. These plots allowed the following to vary:

exposure, sex, genetic ancestry, HbA1c at T2D diagnosis (10th, 50th and 90th percentiles), time, and medication (five profiles, SuppMethods 8). The remaining covariates were fixed at their mode or median. This generated 450 example individuals. Median *P*-values are presented for the within-subject variabililty LRTs.

Sensitivity Analysis

Two sensitivity analyses were performed: a complete case analysis using only participants with non-missing HbA1c at T2D diagnosis (results presented below), and analysis using a broader definition of MDD using initial assessment information and the mental health questionnaire from UKB (results given in SuppMethods 9).

Results

Validation of T2D diagnostic criteria

The eligible UKB sample consisted of 17,689 individuals with T2D (Figure 2), with 25% of individuals having evidence of T2D from all five data sources considered. Participants with T2D tend to be male (61%) with an average age at T2D diagnosis of 59 years (IQR: 52 - 64 years) (Table 1). Applying genetic quality control criteria to participants of European ancestry provided 13,376 T2D cases and 67,529 controls. T2D PGSs were significantly associated with T2D case-control status at all PGS *P*-value thresholds and explained up to 2.9% of T2D liability (SuppTable S6).

Longitudinal analysis

In total, 9264 T2D cases met inclusion criteria for longitudinal analysis. Median follow-up time was 7.6 years (IQR: 4 – 10 years). After assignment to MDD subgroups, 82% had no MDD diagnosis ('no MDD' group), 13% had MDD prior to their T2D diagnosis ('pre-T2D MDD' group) and 5% received a diagnosis of MDD after their T2D diagnosis ('post-T2D MDD' group) (Table 1). Groups with a diagnosis of MDD include a higher proportion of females, whilst the post-T2D MDD group had a 5-year earlier median age at T2D diagnosis, resulting in a longer median follow-up time. The distributions of HbA1c at T2D diagnosis are right skewed with similar medians for all subgroups, but the post-T2D MDD group having a heavier tail (Supplementary Figure (SuppFigure) S1). A higher proportion of the post-T2D MDD group are missing HbA1c at diagnosis (73% compared to 50% for the pre-T2D MDD group and 54% for the no MDD group).

There were no differences in mean HbA1c over T2D disease duration for either MDD group compared to the no MDD group, demonstrated by hypothesis testing (Table 2) and plots of predicted HbA1c over a 10-year T2D disease duration for example individuals. Figure 3 presents 18 example European females defined by MDD subgroup, HbA1c at T2D diagnosis and medication profile. T2D cases with high HbA1c at diagnosis (90th percentile) had decreasing mean HbA1c values for 3.5 years, then a slow increase to 6 years. A more rapid decline is seen for those prescribed monotherapy at diagnosis compared to those with no prescription (profile 4 vs 1). T2D cases with a low (10th percentile) or median HbA1c at diagnosis had a small increase in HbA1c over ten years, with a linear increase for those not

prescribed T2D medication. Trends were similar for all MDD subgroups (SuppFigures S5–S29).

Individuals in the post-T2D MDD group had more variable HbA1c values compared to the no MDD group (median LRT P = 6.357E-50; Table 3), with residual variance 1.14 times greater than the no MDD group (95% CI: 1.12 – 1.16). No difference in residual variation was observed for the pre-T2D MDD group compared to the no MDD group (residual variance ratio, relative to no MDD, estimate: 1.00 (95% CI: 0.94, 1.07), median LRT P = 0.4969). For full model results (pooled and MI dataset specific), see SuppTables S7-S8.

Complete Case Sensitivity Analysis

The complete case sample size reduced from 9264 to 4233 T2D cases, with higher exclusion for the post-T2D MDD group (only 27% retained compared to 50% and 46% for the pre-T2D and no MDD groups). Participants were older at T2D diagnosis, had shorter follow-up with fewer HbA1c observations, and no one was on monotherapy at diagnosis (M1) (SuppTable S13). These results provide strong evidence against individuals being missing completely at random, and results from complete case analyses may be biased. The complete case results (SuppTable S14-S15) differed from the MI results in two key ways. Firstly, a difference in mean HbA1c over time for the pre-T2D MDD group compared to the no MDD group was observed (time interaction P = 0.0073), but not for the post-T2D MDD group (P = 0.2239). Plots for hypothetical individuals (SuppFigures S35–S49) show that differences in mean HbA1c between the pre-T2D MDD and no MDD group are observed later in follow-up (mean HbA1c increases more rapidly for the pre-T2D MDD at ~6 years after T2D diagnosis). Secondly, residual HbA1c is slightly *less* variable for both MDD groups. Compared to the no MDD group, variability in the pre-T2D MDD group was 8% lower (95% CI: 6% - 10%, P = 1.66E-15) and 4% lower for the post-T2D MDD group (95% CI: 1% - 6%, P = 0.0418).

Discussion

This study tested the hypothesis that people with both T2D and MDD have poorer diabetic control over time, as assessed by routine primary care monitoring of HbA1c. We examined whether UKB participants with T2D and MDD have higher, and more variable, HbA1c over time compared to those without MDD. The diagnostic order of T2D and MDD was incorporated by stratifying the MDD exposure group into those diagnosed with MDD prior to T2D or after T2D. Longitudinal modelling across 10 years of follow up using multiple imputation found no differences in mean HbA1c by MDD diagnosis, but more variable within-patient HbA1c measurements in the post-T2D MDD group.

Previous work on mean HbA1c has provided inconclusive evidence for the impact of MDD[10]. However, two larger studies did find associations between mean HbA1c over time and depression- a meta-analysis found a modest association between depressive symptoms and HbA1c (3 year mean follow-up)[10], and a prospective study in veterans with T2D found that HbA1c was slightly higher for individuals with depression (5 year follow-up)[33]. This study found no difference in mean HbA1c by MDD diagnosis. The different conclusions from our study may reflect study characteristics (97% of the veteran study were male), and methodology differences (the veterans study considered linear time only and did not adjust for diabetic medication).

Additionally, our study stratified individuals with MDD by the timing of MDD diagnosis relative to T2D diagnosis (pre-, post). If mean HbA1c over time does not differ by the order of diagnoses, we reduced the power to detect an association. However, a previous study[6] showed differences in T2D clinical characteristics by timing of MDD and T2D diagnoses, with a higher rate of diabetic complications in the post-T2D MDD group, but not the pre-TDD MDD group, compared to the no MDD group. Differences in glycaemic control between these MDD subgroups is a possible explanation for the observed clinical differences. Whilst this study does not support the hypothesis that the post-T2D MDD group would have higher mean HbA1c over time, it does suggest that this group has poorer glycaemic control through greater HbA1c variability, demonstrating the potential importance of the relative timing of MDD onset. Higher HbA1c variability is associated with increased likelihood of adverse outcomes, including microvascular disease[34]. These findings therefore need to be further investigated to ensure appropriate public health and clinical advice is available.

Due to the, at most, modest effect of depression observed in prior studies and the smaller sample size of the post-T2D MDD group (*n*=452), this study may have been underpowered to detect differences in mean HbA1c. Future work using larger samples and more precise methods of capturing the time between T2D and MDD diagnoses (e.g. joint models for HbA1c over time and time-to-MDD diagnosis) could identify such differences, and determine if patients diagnosed with MDD after T2D require closer monitoring, or whether a specific time window is crucial for glycaemic control.

Our findings show that both HbA1c at T2D diagnosis and T2D medication impact HbA1c, with non-linear time trends. For example, a reduction in HbA1c immediately after T2D diagnosis is observed for those with high HbA1c values at diagnosis, and is more pronounced in individuals prescribed monotherapy compared to those prescribed no medication. The increase in HbA1c after 3.5 years suggests further intervention may be required to control diabetes in these individuals. In contrast, a gradual increase in HbA1c occurs for T2D cases with low to median HbA1c levels at diagnosis who receive no T2D medication prescriptions over follow-up.

MDD episodes after T2D diagnosis are hypothesised to have a greater effect on glycaemic control, which we have confirmed by showing greater within-subject variability in the post-T2D MDD group. These individuals visited their GP after their T2D diagnosis and had a MDD code recorded. Multiple pathways, particularly behavioural, could explain this association. Several studies have shown that patients with both MDD and T2D have worse T2D self-management, are less able to keep the medical appointments, are less physically active and less able to adhere to dietary requirements, possibly leading to hyperglycaemia[35–37]. Our study highlights the importance of diagnosis timing, with possible need for targeted interventions based on clinical history.

Our study has several limitations. Firstly, primary care data are collected when patients visit their GP, and between-patient differences in this visiting process can bias results[38,39]. Individuals with T2D should all see their GP every 3-6 months[11] and differences may affect results. For example, less healthy individuals may interact with GPs more frequently and contribute more observations. The models used reduce this potential bias, because the CAR1 error structure ensures that participant observations taken close in time provide less

information than those taken far apart. However, T2D cases with MDD may miss more scheduled appointments, and our analysis does not account for this.

Secondly, as a retrospective, observational study, confounding may bias results. For example, antidepressant medication can lead to weight gain[40], which can negatively affect HbA1c levels[41]. Known risk factors (e.g. antidepressant medication, body composition, cardiovascular conditions) could be included in a follow-up analysis.

Thirdly, HbA1c at T2D diagnosis had a high level of missingness, which disproportionately affected individuals in the post-T2D MDD group, and highlights the challenges of working with real-world data. Since data was not missing completely at random, we used multiple imputation, but this has limitations and depends on the model selected and data availability.

Further limitations relate to the validity of the age at MDD onset, which was defined using the date of the first MDD diagnostic code. For older individuals the validity of their MDD onset is unknown, given primary care records are only available after 1990, while mean age at diagnosis of MDD is around 30 years[42]. A sensitivity analysis incorporating self-reported age at MDD diagnosis supported the main findings, but replication in the Clinical Practice Research Datalink, which has GP records from 1987 and no age limits, would be useful[43].

In conclusion, we used UKB primary care records to test the longitudinal association between MDD and glycaemic control in individuals with T2D. We derived and validated T2D from multiple sources and demonstrated the importance of considering the temporal relationships between T2D and MDD. We found a non-linear trend in mean HbA1c over time and demonstrated that within a 10-year window the pattern of mean HbA1c was consistent across MDD diagnosis subgroups. Importantly, those diagnosed with MDD after T2D onset had greater variability in HbA1c, supporting the finding that individuals with both conditions have poorer health outcomes. Our findings suggest that individuals with T2D who are later diagnosed with MDD have poorer glycaemic control, implying closer monitoring would be useful and may reduce the adverse consequences associated with both T2D and MDD.

Funding

This paper represents independent research part-funded by the National Institute for Health Research (NIHR) Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care. The authors acknowledge use of the research computing facility at King's College London, CREATE[44]. This research as supported by the Medical Research Council (MR/S0151132; MR/N015746). JT and FC are supported by an Academy of Medical Sciences (AMS) Springboard award, which is supported by the AMS, the Wellcome Trust, GCRF, the Government Department of Business, Energy and Industrial strategy, the British Heart Foundation and Diabetes UK [SBF004\1079]. KGY is supported by Research England's Expanding Excellence in England (E3) fund. HG is funded by an E3 Independent Research Fellowship.

Acknowledgements

The authors thank Dr Oliver Pain at King's College London for providing the PGS for MDD. This research has been conducted using the UKB Resource under Application Number 18177. We are grateful to all UKB staff and volunteers.

Competing interests

No potential or existing conflicts of interest relevant to this article were reported.

References

1. Knol MJ, Twisk JWR, Beekman ATF, Heine RJ, Snoek FJ, Pouwer F. Depression as a risk factor for the onset of type 2 diabetes mellitus. A meta-analysis. *Diabetologia*. 2006;49(5):837. doi:10.1007/s00125-006-0159-x

2. Mezuk B, Eaton WW, Albrecht S, Golden SH. Depression and Type 2 Diabetes Over the Lifespan. *Diabetes Care*. 2008;31(12):2383. doi:10.2337/dc08-0985

3. Nouwen A, Adriaanse MC, van Dam K, et al. Longitudinal associations between depression and diabetes complications: A systematic review and meta-analysis. *Diabet Med*. 2019;36(12):1562-1572.

4. Fugger G, Dold M, Bartova L, et al. Major Depression and Comorbid Diabetes - Findings from the European Group for the Study of Resistant Depression. *Prog Neuropsychopharmacol Biol Psychiatry*. 2019;94:109638. doi:10.1016/j.pnpbp.2019.109638

5. Holt RIG, de Groot M, Golden SH. Diabetes and Depression. *Curr Diab Rep*. 2014;14(6):491. doi:10.1007/s11892-014-0491-3

6. Bruce DG, Davis WA, Cetrullo V, Starkstein SE, Davis TME. Clinical Impact of the Temporal Relationship between Depression and Type 2 Diabetes: The Fremantle Diabetes Study Phase II. *PLOS ONE*. 2013;8(12):e81254. doi:10.1371/journal.pone.0081254

7. Martín-Timón I, Sevillano-Collantes C, Segura-Galindo A, Del Cañizo-Gómez F. Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength? *World J Diabetes*. 2014;5(4):444-470. doi:10.4239/wjd.v5.i4.444

8. Gorst C, Kwok CS, Aslam S, et al. Long-term Glycemic Variability and Risk of Adverse Outcomes: A Systematic Review and Meta-analysis. *Diabetes Care*. 2015;38(12):2354-2369. doi:10.2337/dc15-1188

9. Sherwani S, Khan H, Ekhzaimy A, Masood A, Sakharkar M. Significance of HbA1c Test in Diagnosis and Prognosis of Diabetic Patients. *Biomark Insight*. 2016;11:95-104. doi:10.4137/BMI.S38440

10. Beran M, Muzambi R, Geraets A, et al. The bidirectional longitudinal association between depressive symptoms and HbA1c: A systematic review and meta-analysis. *Diabet Med*. Published online 2021:e14671.

11. McGuire H, Longson D, Adler A, Farmer A, Lewin I. Management of type 2 diabetes in adults: summary of updated NICE guidance. *BMJ*. 2016;353:i1575. doi:10.1136/bmj.i1575

12. Sudlow C, Gallacher J, Allen N, et al. UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age. *PLOS Med*. 2015;12(3):e1001779. doi:10.1371/journal.pmed.1001779

13. UK Biobank. Primary Care Linked Data. Published online 2019. https://biobank.ndph.ox.ac.uk/showcase/showcase/docs/primary_care_data.pdf

14. Hagenaars SP, Coleman JRI, Choi SW, et al. Genetic comorbidity between major depression and cardio-metabolic traits, stratified by age at onset of major depression. *Am J Med Genet B Neuropsychiatr Genet*. 2020;183(6):309-330. doi:10.1002/ajmg.b.32807

15. Holm NCR, Belstrøm D, Østergaard JA, Schou S, Holmstrup P, Grauballe MB. Identification of Individuals With Undiagnosed Diabetes and Pre-Diabetes in a Danish Cohort Attending Dental Treatment. *J Periodontol*. 2016;87(4):395-402. doi:10.1902/jop.2016.150266

16. Fabbri C, Hagenaars SP, John C, et al. Genetic and clinical characteristics of treatment-resistant depression using primary care records in two UK cohorts. *Mol Psychiatry*. 2021;26(7):3363-3373. doi:10.1038/s41380-021-01062-9

17. NGSP. IFCC Standardization of HbA1c. http://www.ngsp.org/ifccngsp.asp

18. Young KG, McDonald TJ, Shields BM. Glycated haemoglobin measurements from UK Biobank are different to those in linked primary care records: implications for combining biochemistry data from research studies and routine clinical care. *Int J Epidemiol*. 2022;51(3):1022-1024. doi:10.1093/ije/dyab265

19. Hanscombe K. ukbkings: KCL interface to UKB Project Data on Rosalind/CREATE HPC. https://github.com/kenhanscombe/ukbkings

20. Scott RA, Scott LJ, Mägi R, et al. An Expanded Genome-Wide Association Study of Type 2 Diabetes in Europeans. *Diabetes*. 2017;66(11):2888-2902. doi:10.2337/db16-1253

21. Choi SW, O'Reilly PF. PRSice-2: Polygenic Risk Score software for biobank-scale data. *GigaScience*. 2019;8(7):giz082. doi:10.1093/gigascience/giz082

22. Choi SW, Mak TSH, O'Reilly PF. Tutorial: a guide to performing polygenic risk score analyses. *Nat Protoc*. 2020;15(9):2759-2772. doi:10.1038/s41596-020-0353-1

23. Pinheiro J, Bates D. *Mixed-Effects Models in S and S-PLUS*. Springer, New York; 2000. https://doi.org/10.1007/b98882

24. Pinheiro J, Bates D, R Core Team. nlme: Linear and Nonlinear Mixed Effects Models. Published online 2022. https://CRAN.R-project.org/package=nlme

25. Harrell F. *Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis*. Vol 608. Springer; 2001.

26. Gauthier J, Wu QV, Gooley TA. Cubic splines to model relationships between continuous variables and outcomes: a guide for clinicians. *Bone Marrow Transplant*. 2020;55(4):675-680. doi:10.1038/s41409-019-0679-x

27. Honaker J, King G, Blackwell M. Amelia II: A Program for Missing Data. *J Stat Softw*. 2011;45(7):1-47. doi:10.18637/jss.v045.i07

28. Li KH, Meng XL, Raghunathan TE, Rubin DB. SIGNIFICANCE LEVELS FROM REPEATED p-VALUES WITH MULTIPLY-IMPUTED DATA. *Stat Sin*. 1991;1(1):65-92.

29. Marshall A, Altman DG, Holder RL, Royston P. Combining estimates of interest in prognostic modelling studies after multiple imputation: current practice and guidelines. *BMC Med Res Methodol*. 2009;9(1):57. doi:10.1186/1471-2288-9-57

30. Shepherd BE, Rebeiro PF, the Caribbean C and SA network for H epidemiology. Brief Report: Assessing and Interpreting the Association Between Continuous Covariates and Outcomes in Observational Studies of HIV Using Splines. *JAIDS J Acquir Immune Defic Syndr*. 2017;74(3). https://journals.lww.com/jaids/Fulltext/2017/03010/Brief_Report__Assessing_and_Interpreting_the.7.aspx

31. Perperoglou A, Sauerbrei W, Abrahamowicz M, Schmid M. A review of spline function procedures in R. *BMC Med Res Methodol*. 2019;19(1):46. doi:10.1186/s12874-019-0666-3

32. Miles A. Obtaining Predictions from Models Fit to Multiply Imputed Data. *Sociol Methods Res*. 2016;45(1):175-185. doi:10.1177/0049124115610345

33. Richardson LK, Egede LE, Mueller M, Echols CL, Gebregziabher M. Longitudinal effects of depression on glycemic control in veterans with Type 2 diabetes. *Gen Hosp Psychiatry*. 2008;30(6):509-514. doi:10.1016/j.genhosppsych.2008.07.001

34. Škrha J, Šoupal J, Škrha J, Prázný M. Glucose variability, HbA1c and microvascular complications. *Rev Endocr Metab Disord*. 2016;17(1):103-110. doi:10.1007/s11154-016-9347-2

35. Schmitt A, Reimer A, Hermanns N, et al. Depression is linked to hyperglycaemia via suboptimal diabetes self-management: A cross-sectional mediation analysis. *J Psychosom Res*. 2017;94:17-23. doi:10.1016/j.jpsychores.2016.12.015

36. Lustman PJ, Clouse RE. Depression in diabetic patients: The relationship between mood and glycemic control. *J Diabetes Complications*. 2005;19(2):113-122. doi:10.1016/j.jdiacomp.2004.01.002

37. Gonzalez JS, Peyrot M, McCarl LA, et al. Depression and Diabetes Treatment Nonadherence: A Meta-Analysis. *Diabetes Care*. 2008;31(12):2398. doi:10.2337/dc08-1341

38. Lokku A, Lim LS, Birken CS, Pullenayegum EM, on behalf of the TARGet Kids! Collaboration. Summarizing the extent of visit irregularity in longitudinal data. *BMC Med Res Methodol*. 2020;20(1):135. doi:10.1186/s12874-020-01023-w

39. Kalia S, Saarela O, Escobar M, Moineddin R, Greiver M. Estimation of marginal structural models under irregular visits and unmeasured confounder: calibrated inverse probability weights. *BMC Med Res Methodol*. 2023;23(1):4. doi:10.1186/s12874-022-01831-2

40. Gafoor R, Booth HP, Gulliford MC. Antidepressant utilisation and incidence of weight gain during 10 years' follow-up: population based cohort study. *BMJ*. 2018;361. doi:10.1136/bmj.k1951

41. Gummesson A, Nyman E, Knutsson M, Karpefors M. Effect of weight reduction on glycated haemoglobin in weight loss trials in patients with type 2 diabetes. *Diabetes Obes Metab*. 2017;19(9):1295-1305. doi:10.1111/dom.12971

42. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication. *Arch Gen Psychiatry*. 2005;62(6):593-602. doi:10.1001/archpsyc.62.6.593

43. Herrett E, Gallagher AM, Bhaskaran K, et al. Data Resource Profile: Clinical Practice Research Datalink (CPRD). *Int J Epidemiol*. 2015;44(3):827-836. doi:10.1093/ije/dyv098

44. King's College London. King's Computational Research, Engineering and Technology Environment (CREATE). Published 2022. https://doi.org/10.18742/rnvf-m076

45. Grund S, Robitzsch A, Luedtke O. mitml: Tools for Multiple Imputation in Multilevel Modeling. Published online 2021. https://CRAN.R-project.org/package=mitml

Figures and tables

Figure 1. Flow diagram of UK Biobank participant selection.

T2D = type 2 diabetes. MDD = major depressive disorder. HES = hospital episode statistics. HbA1c = glycated haemaglobin. Individuals included in the validation of T2D diagnosis are T2D case and controls of European ancestry, meeting eligibility criteria outlined in Methods, including individual-level genetic analysis inclusion criteria (described in SuppMethods 4). Longitudinal data analysis is restricted to participants with a T2D diagnosis.

Table 1: Characteristics of the UKB T2D sample for all T2D cases and longitudinal data analysis T2D sample stratifyied by MDD subgroup

	UKB T2D cases *(n=17,689)*	**Longitudinal analysis sample by MDD subgroup** *(n=9264)*		
		No MDD *(n=7627)*	**Pre-T2D MDD** *(n=1185)*	**Post-T2D MDD** *(n=452)*
Female	6900 (39%)	2350 (31%)	657 (55%)	201 (44%)
Year of birth	1947 (1943, 1953)	1947 (1943, 1953)	1949 (1945, 1955)	1949 (1944, 1955)
Genetic ancestry				
European	14,680 (83%)	6755 (89%)	1113 (94%)	399 (88%)
African	374 (2%)	182 (2%)	13 (1%)	8 (2%)
Admixed	95 (0.5%)	44 (0.6%)	7 (0.6%)	5 (1%)
East Asian	107 (0.6%)	69 (0.9%)	3 (0.3%)	3 (0.7%)
South Asian	1152 (7%)	577 (8%)	49 (4%)	37 (8%)
Missing	1030 (6%)	-	-	-
MDD diagnosis				
No. individuals	1956 (11%)	-	1185 (100%)	452 (100%)
Age (years)	51.6 (44.5, 58.3)[a]	-	49.0 (42.2, 55.7)	58.3 (52.4, 63.6)
Measurements at T2D diagnosis				
Year	2008 (2003, 2011)	2008 (2004, 2011)	2009 (2006, 2013)	2003 (2000, 2006)
Age (years)	58.5 (51.7, 64.0)	59.5 (53.4, 64.9)	59.1 (53.6, 64.2)	53.7 (47.4, 58.6)
HbA1c (mmol/mol)	53.0 (50.0, 63.0)	53.0 (50.0, 63.6)	52.0 (50.0, 59.8)	53.0 (50.0, 66.0)
Missing HbA1c	10,162 (57%)	4110 (54%)	589 (50%)	332 (73%)
No measurement within +/- 6 months	4460 (25%)	1593 (21%)	131 (11%)	176 (39%)
No measurement within +/- 1 year	3733 (21%)	1259 (17%)	96 (8%)	149 (33%)
Prescribed monotherapy	848 (5%)	368 (5%)	58 (5%)	23 (5%)
Follow-up (years)[b]	8.3 (4.5, 12.9)	7.6 (4.2, 9.6)	6.6 (3.1, 9.2)	9.6 (8.5, 9.8)
No. observations	14 (7, 24)	11 (5, 17)	11 (5, 18)	16 (10, 22)

Values presented are either counts (%) or the median (interquartile range).

a. Calculated for 1892 individuals with an MDD diagnosis date available. b. Follow-up: UKB T2D cases = last available HbA1c measurement (up to 2017), Longitudinal analysis sample = last available HbA1c measurement observed during the first 10 years since T2D diagnosis (up to 2017).

Figure 2: Contributions of each input T2D phenotype. Horizontal bars indicate the number of individuals who met criteria for the corresponding T2D phenotypes. Vertical bars indicate the number of individuals endorsing combinations of the five T2D phenotypes. Light blue bars indicate particpants identified by a single T2D phenotype, who did not meet our inclusion criterion for T2D cases and are therefore removed from subsequent analyses.

Table 2: Pooled hypothesis test results for the MDD subgroup fixed effects from the mixed effects models using MI datasets.

MDD subgroups	Main effects		Interactions with T2D disease duration[a]	
	F-test statistic (df1, df2[c])	*P*-value	**F-test statistic (df1, df2[c])**	*P*-value
Pre-T2D MDD[b]	0.572 (1, 4531.639)	0.4495	2.258 (3, 4.084e+06)	0.0795
Post-T2D MDD[b]	1.446 (1, 4399.630)	0.2292	2.096 (3, 23981.900)	0.0945
Any MDD[b]	1.057 (2, 2379.967)	0.3477	2.088 (6, 39262.191)	0.0512

Pooled F-test statistics and p-values were obtained using the mitml package in R[45] (known as Wald-like tests) via the D2 method from Li, Meng, Raghunathan and Rubin (1991)[28]. Fixed effects are tested using models estimated via maximum likelihood. a. T2D disease duration was modelled as a restricted cubic spline with four knots, giving disease duration three variables. b. Reference category is 'No MDD', and so the null hypothesis is that the main, or time-interaction, effects for the group(s) specified are equal to the 'No MDD' group. Any MDD is both the pre-T2D MDD and post-T2D MDD groups. c. df = degrees of freedom, with df1 referring to the number of parameters contrained to be zero under the null (numerator df) and df2 referring to the denominator df under the D2 method.

Figure 3: Pooled predicted HbA1c (mmol/mol), with 95% CI (dashed lines), over T2D disease duration for 18 example European females, defined by varying MDD subgroup (colour), medication profile (columns) and HbA1c percentile at T2D diagnosis (rows).

Pooled predictions are based on the fixed effects models from the 15 MI datasets used. HbA1c percentiles: 10th = 49 mmol/mol, 50th = 53 mmol/mol, 90th = 88 mmol/mol. Medication profile 1 = no monotherapy prescription at baseline, no T2D medication prescribed during follow-up. Medication profile 4 = monotherapy prescribed at baseline, monotherapy prescribed during follow-up, no additional T2D medications prescribed. Covariates held constant: sex = female, genetic ancestry = European, year of birth = 1947, year of diagnosis = 2008, age at T2D diagnosis = 61, assessment centre = 11010.

Table 3: Pooled hypothesis test results for within-subject residual variability in HbA1c differing by MDD subgroup, using multiple imputation datasets.

MDD subgroup	Residual variance form	Parameter	Estimate (95% CI)	Median LRT *P*-value
No MDD	$C_0 \sigma_R^2$	C_0	1	
Pre-T2D MDD	$C_1 \sigma_R^2$	C_1	1.00 (0.94, 1.07)	0.4969
Post-T2D MDD	$C_2 \sigma_R^2$	C_2	1.14 (1.12, 1.16)	6.357E-50

LRT = likelihood ratio test. σ_R^2 = residual variance, where $\hat{\sigma}_R$ = 0.536 (95% CI: [0.530, 0.542]). Residual variance form for MDD subgroups was specified using the varIdent function in the models 'weights' input. See SuppMethods 10 and nlme package help documentation for details.